AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarubbi, F A
Right arrow Articles by Berk, S L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarubbi, F A
Right arrow Articles by Berk, S L

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1989 January; 33(1): 113-114

In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

F A Sarubbi, A Verghese, C Caggiano, S Holtsclaw-Berk and S L Berk

Division of Infectious Diseases, Veterans Administration Medical Center, Johnson City, Tennessee.

ABSTRACT

Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against Branhamella catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against beta-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of less than or equal to 2.0 micrograms/ml.

Antimicrob Agents Chemother. 1989 January; 33(1): 113-114






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1989 by the American Society for Microbiology. All rights reserved.